Licensing Partners Hsiri’s history of partnering with Shionogi for non-tuberculous mycobacterial diseases and TB highlights its openness to licensing and co-development. With a focus on MDR gram-negative bacteria and mycobacterial infections, the company could be a strategic target for license or collaboration deals with mid-to-large pharma and biotech players pursuing innovative antibiotics.

External R&D Support As a very small team, Hsiri is likely to rely on external CROs, CMOs, and research partners for preclinical work, early development, and regulatory support. This creates opportunities for BD teams to position end-to-end R&D partnerships, milestone-based services, and outsourcing arrangements to accelerate progress.

GMP Manufacturing Lead candidates in MDR antibiotics require scalable GMP production and supply. Hsiri could partner with contract manufacturers for process development and clinical materials supply to speed up clinical programs and reduce capital needs.

Funding Opportunities With modest revenue and private status, Hsiri may be receptive to non-dilutive funding, grant programs, and milestone-based licensing deals. Aligning proposals with antibiotic resistance funding initiatives and pull incentives could unlock financing for development.

Regional Ecosystem Located in Media, Pennsylvania, Hsiri sits in the East Coast biotech ecosystem with access to nearby universities, CROs, and service providers. Proximity can enable faster partnerships, access to specialized talent, and collaboration opportunities to support drug discovery and development.